FDA Approves New Oral Option for Plaque Psoriasis - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

  • By

  • Kathryn Wighton

  • March 18, 2026

  • 2 min

Share

Original Source(s)

FDA Approves New Oral Option for Plaque Psoriasis

  • by Kathryn Wighton

  • March 18, 2026

Related Content

Errors in Table 2

  • July 1, 2026

Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010–2025)

Reanalysis of the immunological characteristics of scalp psoriasis: a cross-sectional study using Olink proteomics